These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 37809064)
1. The role of APOBEC3C in modulating the tumor microenvironment and stemness properties of glioma: evidence from pancancer analysis. Zhang S; Guo Y; Hu Y; Gao X; Bai F; Ding Q; Hou K; Wang Z; Sun X; Zhao H; Qu Z; Xu Q Front Immunol; 2023; 14():1242972. PubMed ID: 37809064 [TBL] [Abstract][Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas. Zhao S; Li Y; Xu J; Shen L Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705 [TBL] [Abstract][Full Text] [Related]
3. A pan-cancer landscape of IGF2BPs and their association with prognosis, stemness and tumor immune microenvironment. Shao W; Zhao H; Zhang S; Ding Q; Guo Y; Hou K; Kan Y; Deng F; Xu Q Front Oncol; 2022; 12():1049183. PubMed ID: 36686749 [TBL] [Abstract][Full Text] [Related]
4. Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma. Li YC; Wu Y; Chen G; Zhu LZ; Luo X; Nie QQ; Zhang L; Zuo CJ Sci Rep; 2023 Aug; 13(1):13317. PubMed ID: 37587203 [TBL] [Abstract][Full Text] [Related]
5. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the prognostic and immunological signature of eight Tripartitemotif (TRIM) family molecules in human gliomas. Lu J; Liang K; Zou R; Peng Y; Wang H; Huang R; Zeng Z; Feng Z; Fan Y; Zhang S; Ji Y; Pang X; Wang Y; Zhang H; Wang Z Aging (Albany NY); 2023 Jun; 15(12):5798-5825. PubMed ID: 37367937 [TBL] [Abstract][Full Text] [Related]
7. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers]. Liu J; Xu K; Ma L; Wang Y Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410 [TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of the prognostic value and immune microenvironment of lysosome-dependent cell death in glioma: Including glioblastoma and low-grade glioma. Li W; Wang J; Tang C Medicine (Baltimore); 2024 Feb; 103(6):e36960. PubMed ID: 38335383 [TBL] [Abstract][Full Text] [Related]
9. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis. Qi C; Lei L; Hu J; Wang G; Liu J; Ou S J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801 [TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma. Xu L; Shao F; Luo T; Li Q; Tan D; Tan Y Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955624 [TBL] [Abstract][Full Text] [Related]
11. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma. Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J Front Immunol; 2023; 14():1220100. PubMed ID: 37662954 [TBL] [Abstract][Full Text] [Related]
12. Association of glioma CD44 expression with glial dynamics in the tumour microenvironment and patient prognosis. Du Z; Wang Y; Liang J; Gao S; Cai X; Yu Y; Qi Z; Li J; Xie Y; Wang Z Comput Struct Biotechnol J; 2022; 20():5203-5217. PubMed ID: 36187921 [TBL] [Abstract][Full Text] [Related]
13. Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response. Ye S; Yang B; Yang L; Wei W; Fu M; Yan Y; Wang B; Li X; Liang C; Zhao W Sci Rep; 2024 Jun; 14(1):14758. PubMed ID: 38926605 [TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma. Zuo S; Wei M; Wang S; Dong J; Wei J Front Immunol; 2020; 11():1218. PubMed ID: 32714316 [No Abstract] [Full Text] [Related]
15. Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118 [TBL] [Abstract][Full Text] [Related]
16. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma. Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S Front Immunol; 2023; 14():1128244. PubMed ID: 37818357 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas. Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109 [TBL] [Abstract][Full Text] [Related]
18. Role of COL6A2 in malignant progression and temozolomide resistance of glioma. Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657 [TBL] [Abstract][Full Text] [Related]
19. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Potential of Secreted Modular Calcium-Binding Protein 1 in Low-Grade Glioma. Wang J; Xia S; Zhao J; Gong C; Xi Q; Sun W Front Mol Biosci; 2021; 8():666623. PubMed ID: 34869577 [No Abstract] [Full Text] [Related] [Next] [New Search]